BURLINGTON…TriPath Imaging Inc. (Nasdaq:TPTH) says experts at top U.S. institutions will test two new experimental molecular diagnostic tests for cervical and breast cancer.

The company says that experts at Johns Hopkins, Massachusetts General, and the University of Colorado Health and Sciences Center will test its new cervical cancer diagnostic.

Cervical cancer is the third most common for women in the U.S., with 10,520 new cases and 3,900 deaths a year according to the National Cancer Society. Every year, 50 to 60 million women are screened for the disease.

The company says it has approached the U.S. Food and Drug Administration regarding design of a clinical trial to support a potential application for pre-market approval of the test, which works with TriPath’s proprietary SurePath test pack.

It says top researchers will also evaluate the potential of its new breast cancer test, which it says may help patients and doctors make individualized decisions on treatment based on molecular testing as part of the overall evaluation.